Filing Flows › Accendra Health (ACH) › Q3 2026 › vs Q3 2025
Accendra Health (ACH) Q3 2026 vs Q3 2025 (year over year)
Accendra Health's revenue fell $95.5M (-14%) from $697M in Q3 2025 to $602M in Q3 2026. The biggest changes: Sleep therapy −$41.3M (-22%); Other −$25.4M (-35%); Home respiratory therapy −$18.3M (-17%).
Accendra Health, Q3 2026: revenue $602M (-14% year over year), operating margin 0.2%, net loss $19.7M, operating cash flow −$17.4M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Diabetes | $196M | $201M | −$5.8M | -3% |
| Sleep therapy | $144M | $186M | −$41.3M | -22% |
| Home respiratory therapy | $88.9M | $107M | −$18.3M | -17% |
| Ostomy | $55.2M | $53.3M | $2.0M | +4% |
| Other | $47.2M | $72.6M | −$25.4M | -35% |
| Wound care | $41.6M | $48.0M | −$6.4M | -13% |
| Urology | $28.7M | $29.0M | −$266K | -0.9% |
| Revenue | $602M | $697M | −$95.5M | -14% |
| Income tax benefit | $18.9M | −$2.0M | $20.8M | — |
| Net loss | $19.7M | $150M | −$131M | -87% |
| Costs & expenses | $640M | $848M | −$207M | -24% |
| Operating costs | $600M | $671M | −$70.4M | -10% |
| Interest & other, net | $39.9M | $175M | −$135M | -77% |
| Cost of revenue | $340M | $375M | −$34.6M | -9% |
| SG&A | $249M | $266M | −$16.4M | -6% |
| Other operating costs | $10.5M | $29.9M | −$19.4M | -65% |
| Operating cash sources | $58.4M | $237M | −$178M | -75% |
| Depreciation & amortization | $38.9M | $64.1M | −$25.2M | -39% |
| Share-based compensation | $2.1M | $0 | $2.1M | — |
| Cash used in operations | $17.4M | $173M | −$155M | -90% |
| Net loss absorbed | $19.7M | $150M | −$131M | -87% |
| Working capital & other | $38.7M | $86.3M | −$47.6M | -55% |
Questions
How much did Accendra Health's revenue grow year over year in Q3 2026?
Accendra Health's revenue fell $95.5M (-14%) from $697M in Q3 2025 to $602M in Q3 2026.
What drove Accendra Health's revenue change in Q3 2026?
Sleep therapy −$41.3M (-22%); Other −$25.4M (-35%); Home respiratory therapy −$18.3M (-17%).